Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, is associated with HIV disease progression in resource-constrained settings

for the NWCS 319 and PEARLS Study Team

Research output: Contribution to journalArticle

Abstract

A case-cohort analysis of human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART) was performed within a multicountry randomized trial (PEARLS) to assess the prevalence of persistently elevated C-reactive protein (CRP) levels, based on serialmeasurements of CRP levels, and their association with HIV clinical failure. A persistently elevated CRP level in plasma (defined as ≥5 mg/L at both baseline and 24 weeks after ART initiation) was observed in 50 of 205 individuals (24%). A persistently elevated CRP level but not an elevated CRP level only at a single time point was independently associated with increased clinical failure, compared with a persistently low CRP level, despite achievement of virologic suppression. Serial monitoring of CRP levels could identify individuals who are at highest risk of HIV progression and may benefit from future adjunct antiinflammatory therapies.

Original languageEnglish (US)
Pages (from-to)1074-1078
Number of pages5
JournalJournal of Infectious Diseases
Volume213
Issue number7
DOIs
StatePublished - 2016

    Fingerprint

Keywords

  • Antiretroviral therapy
  • CRP
  • HIV
  • Inflammation
  • Persistent inflammation

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this